Meet our team at booth #31 during the 7th edition, Cell and Gene Therapy World Asia at Equarius hotel in Singapore on September 14th -15th, 2023. We will be presenting our Poster on Development of a novel helper plasmid: one step closer to the next generation rAAV vectors.

Our team

About Kevin POT
Business Manager, ANZ, SEA & India
Aucune information.
About Thomas Lejolly
Business Director APAC
Aucune information.

Poster: Development of a novel helper plasmid: one step closer to the next generation rAAV vectors.

By : Eric Mauro, Jonathan Havard, Sylvain Julien, Laure Robert, Carine Morel, Patrick Erbacher

Harnessing rAAVs as viral vectors for therapeutic transgene delivery still requires improvements in yields and specificity to lower vector doses, and therefore manufacturing cost, as well as to improve patient safety. To this end, our research is focused on developing novel technologies to ensure manufacturing of high yielding rAAV particles using transient transfection, as well as enhancing features of rAAV vectors that act on the overall size of packaged material and specificity of delivery. Here we present our state-of-the art approach to design new helper plasmids (phelpers) with the aim of improving both the infectiosity (TU/mL) and the quality (full/empty ratio) of the viral particle obtained from suspension cultures. We took the opportunity to exploit our proprietary DNA assembly method technology to explore the synergies of multiple genetic features modularly assembled in synthetic plasmids. Comparison of the biological activity of several versions of rationally designed pHelpers led us to identify the optimal configuration able to outperform existing helper plasmids in every tested bioproduction conditions. Our expertise in DNA plasmid design and assembly together with our scalable transfection solutions for rAAV manufacturing gives us the potential to improve both productivity and specificity of gene therapy products.

Download Poster